Damla Gündüz Karayazı

Damla Gündüz Karayazı

Auto-generated profile, based on publicly available information

Damla Gündüz Karayazı

Dokuz Eylul Univ, Dept Chest Dis, Fac Med, Izmir, Turkiye

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2022 in Tuberk Toraks
Verified
Journal Article
Closed access
EUEyüp Sabri Uçan
Eyüp Sabri Uçan
AAAylin Ozgen Alpaydin
Aylin Ozgen Alpaydin
DKDamla Gündüz Karayazı
Damla Gündüz Karayazı
MKMurat Kapkaç
Murat Kapkaç
BTBurça Takar
Burça Takar
MYMehmet Rasih Yılmaz
Mehmet Rasih Yılmaz
Tuberculosis (TB) mastitis is a rare form of granulomatous mastitis. We aimed to evaluate the clinical characteristics and prognosis of patients diagnosed with TB mastitis. A descriptive study was carried out on patients who were reported to national tuberculosis control authorities as having TB mastitis between 2003 and 2021. Demographic, histopathological, and radiological data including mammography, ultrasonography (US), and magnetic resonance imaging (MRI) were reviewed. All were followed up to 24 months and prognosis was also evaluated. This study identified 29 TB mastitis patients who had been diagnosed using excisional biopsies. The mean age was 33.5 ± 10.1, all were premenopausal women. The most common symptom was breast mass (n= 24, %82.8), nearly half of the patients also had ipsilateral axillary lymphadenopathy (n= 14, 48.3). One-fourth of the patients had bilateral involvement (n= 7, 24.1%), and half of the patients (n= 16, 55.2%) presented with multiple masses. One patient had co-existing pulmonary TB. Predisposing factors for TB were not identified in any of the patients. Nearly half of the patients received prior mastitis treatment. The most common radiological finding was mass in both mammography and US. All patients received anti-tuberculosis treatment of a standard regimen for six to 21 months, three patients had a relapse but were finally cured. TB mastitis should be suspected in young and premenopausal women presenting with a breast mass and axillary lymphadenopathy in an endemic region. Radiological findings could not identify the diagnosis. A multidisciplinary approach including bacteriology and histopathology should be performed. Anti-tuberculosis treatment can be implemented successfully.

16 January 2024 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
MBMelike Mese- Buran
Melike Mese- Buran
SSSema Savci
Sema Savci
ATAylin Tanriverdi
Aylin Tanriverdi
BKBuse Ozcan Kahraman
Buse Ozcan Kahraman
DGDamla Gunduz
Damla Gunduz
CSCan Sevinc
Can Sevinc
Objectives: This study primarily aimed to investigate the clinical determinants of the Modified Incremental Step Test (MIST) in adults with non-cystic fibrosis bronchiectasis (NCFB). A secondary objective was to compare the cardiopulmonary responses after the MIST and Incremental Shuttle Walk Test (ISWT), two commonly adopted symptomlimited maximum field tests in chronic respiratory diseases. Methods: Forty- six patients with clinically stable bronchiectasis participated in this cross-sectional study. MIST and ISWT were performed to determine exercise capacity, while disease severity, fatigue, and quality of life were assessed using the Bronchiectasis Severity Index (BSI), the Fatigue Severity Scale (FSS), and St. George's Respiratory Questionnaire (SGRQ), respectively. Quadriceps muscle strength was evaluated using a hand-held dynamometer, walking speed with a wireless inertial sensing device, and the level of physical activity (steps/day) with a pedometer. Results: The BSI score, quadriceps muscle strength, daily step count, and the SGRQ total score explained 61.9% of the variance in the MIST (p < 0.001, R2 = 0.67, AR2 = 0.619). The BSI score (r = -0.412, p = 0.004), quadriceps muscle strength (r = 0.574, p = 0.001), daily step count (r = 0.523, p < 0.001), walking speed (r = 0.402, p = 0.006), FSS score (r = -0.551, p < 0.001), and SGRQ total score (r = - 0.570, p < 0.001) correlated with the MIST. The patients achieved higher heart rates (HR), HR%, desaturation, dyspnea, and leg fatigue in the MIST compared to the ISWT (p < 0.05). Conclusions: Disease severity, quadriceps muscle strength, physical activity level, and quality of life were determinants of MIST. The advantages of the MIST, including higher cardiopulmonary response than ISWT and greater portability, which facilitates its use in various settings, make MIST the preferred choice for investigating symptom-limited exercise capacity in patients with NCFB.

9 September 2023 in European Respiratory Journal
Verified
Conference Paper
Closed access
DKDamla Gündüz Karayazı
Damla Gündüz Karayazı
GŞGökçen Ömeroğlu Şimşek
Gökçen Ömeroğlu Şimşek
CSCan Sevinç
Can Sevinç
Background: Although severe asthma accounts for a small proportion of asthma cases, it accounts for more than half of asthma-related costs due to frequent emergency room visits, hospitalizations, and medication costs. Aim: This study aimed to evaluate 10-year real-life data of patients using omalizumab for severe asthma in a single-center outpatient clinic. Methods: Patients who followed up for severe asthma between 2009 and 2019 were included in the study. The symptoms, the frequency of asthma attacks, the history of hospitalization due to asthma, asthma control tests, the treatments, spirometry results, blood IgE and eosinophil values, and skin prick tests were evaluated. Results: A total of 106 patients, 77 (72.6%) using omalizumab and 29 (27.4%) not using omalizumab, were evaluated in this study. There was no significant difference between demographic data, baseline symptoms, and pulmonary function tests in the initial evaluations of patients between the two groups. An average increase of 150 ml in FEV1 (p=0.006) and 200 ml in FVC (p<0.001) value was detected in the omalizumab group, then the not using omalizumab group. In patients using omalizumab, there was an increase in AKT scores (p<0.001), a decrease in hospitalization (p=0.003), and systemic steroid use (p<0.001) compared to non-users. Conclusion: The results of our study show that initiation of omalizumab treatment in eligible patients contributes to clinical control and an increase in quality of life.

1 September 2022 in Turkish Thoracic Journal
Verified
Journal Article
Open access
MKMahmut Kaya
Mahmut Kaya
GSGokcen Omeroglu Simsek
Gokcen Omeroglu Simsek
EUEyup Sabri Ucan
Eyup Sabri Ucan
FAFerdane Atas
Ferdane Atas
DGDamla Gunduz
Damla Gunduz
ASAli Osman Saatci
Ali Osman Saatci
Diagnosis,Intraocular Tuberculosis,Uveitis,Treatment